Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice

Autor: Eriya Kenjo, Hiroyuki Hozumi, Yukimasa Makita, Kumiko A. Iwabuchi, Naoko Fujimoto, Satoru Matsumoto, Maya Kimura, Yuichiro Amano, Masataka Ifuku, Youichi Naoe, Naoto Inukai, Akitsu Hotta
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Zdroj: Nature Communications, Vol 12, Iss 1, Pp 1-13 (2021)
Druh dokumentu: article
ISSN: 2041-1723
DOI: 10.1038/s41467-021-26714-w
Popis: In vivo delivery of CRISPR-Cas9 holds promise for treating muscular dystrophy, however, AAV delivery is known to be immunogenic. Here, the authors show that LNP delivery of CRISPR-Cas9 enables repeated injections into skeletal muscle and leads to restored dystrophin expression in multiple muscle groups.
Databáze: Directory of Open Access Journals